Jardiance

New Analysis Suggests that Jardiance Could Add Years to Life Expectancy of Adults With Type 2 Diabetes and Cardiovascular Disease
New Analysis Suggests that Jardiance Could Add Years to Life Expectancy of Adults With Type 2 Diabetes and Cardiovascular Disease
CP Wire
Jardiance
Boehringer Ingelheim
Eli Lilly
diabetes
type 2 diabetes
Flag link:
New Analysis Suggests that Jardiance Could Add Years to Life Expectancy of Adults With Type 2 Diabetes and Cardiovascular Disease
Jardiance
Boehringer Ingelheim
Eli Lilly
Flag link:
CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes
CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes
CP Wire
CHMP
Boehringer Ingelheim
Eli Lilly
EMA
Jardiance
Synjardy
Glyxambi
diabetes
Flag link:
CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes
Boehringer Ingelheim
Eli Lilly
Jardiance
Synjardy
Glyxambi
Flag link:
5 Biggest Blockbuster Diabetes Drugs of the Future
5 Biggest Blockbuster Diabetes Drugs of the Future
Motley Fool
Eli Lilly
Trulicity
Novo Nordisk
Ozempic
Boehringer Ingelheim
Jardiance
Tresiba
NovoRapid
Flag link:
Novo Nordisk's oral diabetes drug beats Jardiance in study
Novo Nordisk's oral diabetes drug beats Jardiance in study
Yahoo/Reuters
diabetes
Novo Nordisk
semaglutide
Jardiance
Eli Lilly
Flag link:
Lilly, Boehringer add two Jardiance heart failure studies to examine effects on exercise
Lilly, Boehringer add two Jardiance heart failure studies to examine effects on exercise
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
Jardiance
heart failure
exercise
diabetes
Flag link:
Boehringer strikes Jardiance outcomes deal with Prime PBM
Boehringer strikes Jardiance outcomes deal with Prime PBM
Biopharma Dive
Boehringer Ingelheim
Jardiance
PBMs
diabetes
Prime Therapeutics
outcomes-based contracts
Flag link:
Boehringer Ingelheim inks outcomes-based contract with pharmacy benefit manager for diabetes drug
Boehringer Ingelheim inks outcomes-based contract with pharmacy benefit manager for diabetes drug
Drug Delivery Business News
Boehringer Ingelheim
PBMs
outcomes-based contracts
diabetes
Jardiance
Prime Therapeutics
Flag link:
J&J, Lilly and AZ diabetes medications get another helping of real-world heart benefits
J&J, Lilly and AZ diabetes medications get another helping of real-world heart benefits
Fierce Pharma
JNJ
Eli Lilly
AstraZeneca
Boehringer Ingelheim
diabetes
Invokana
Farxiga
Jardiance
Flag link:
Lilly: Jardiance Reduces Risk Of Cardiovascular Death In Type 2 Diabetes And PAD
Lilly: Jardiance Reduces Risk Of Cardiovascular Death In Type 2 Diabetes And PAD
NASDAQ.com
Jardiance
Eli Lilly
type 2 diabetes
PAD
Flag link:
Boehringer's new risk-prediction model will tap patients who could be good Jardiance candidates
Boehringer's new risk-prediction model will tap patients who could be good Jardiance candidates
Fierce Pharma
Boehringer Ingelheim
Eli Lilly
Jardiance
diabetes
Flag link:
EASD: Boehringer Ingelheim, Lilly's Jardiance holds CV benefit regardless of blood sugar starting point
EASD: Boehringer Ingelheim, Lilly's Jardiance holds CV benefit regardless of blood sugar starting point
Fierce Pharma
EASD
Boehringer Ingelheim
Eli Lilly
Jardiance
diabetes
Flag link:
J&J's Invokana continues downward market-share spiral as Lilly, BI's Jardiance advances
J&J's Invokana continues downward market-share spiral as Lilly, BI's Jardiance advances
Fierce Pharma
JNJ
Invokana
Eli Lilly
Boehringer Ingelheim
Jardiance
diabetes
Flag link:
BI, Lilly hit the streets to talk up Jardiance's cardiovascular benefits
BI, Lilly hit the streets to talk up Jardiance's cardiovascular benefits
Fierce Pharma
Boehringer Ingelheim
Eli Lilly
Jardiance
drug ads
DTC advertising
Flag link:
For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive
For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive
Medical Marketing and Media
diabetes
blood sugar
competition
Novo Nordisk
Victoza
Eli Lilly
Jardiance
Invokana
JNJ
Flag link:
AstraZeneca, Boehringer cry 'no class effect' after Johnson & Johnson's Invokana doubles amputations in study
AstraZeneca, Boehringer cry 'no class effect' after Johnson & Johnson's Invokana doubles amputations in study
Fierce Pharma
AstraZeneca
Boehringer Ingelheim
JNJ
Invokana
diabetes
Jardiance
amputation
Flag link:
J&J's Invokana lowers CV risk, but by enough to compete?
J&J's Invokana lowers CV risk, but by enough to compete?
BioPharma Dive
JNJ
Invokana
diabetes
Jardiance
Eli Lilly
Boehringer Ingelheim
Flag link:
ADA: Merck, Pfizer notch success, but late with SGLT-2 data
ADA: Merck, Pfizer notch success, but late with SGLT-2 data
BioPharma Dive
diabetes
Merck
Pfizer
SGLT2 inhibitor
Januvia
Invokana
Farxiga
Jardiance
Eli Lilly
Boehringer Ingelheim
AstraZeneca
JNJ
Flag link:
J&J Drug Prevents Heart Attacks At Cost Of Amputated Toes
J&J Drug Prevents Heart Attacks At Cost Of Amputated Toes
Forbes
JNJ
heart attacks
Invokana
diabetes
amputation. Eli Lilly
Boehringer Ingelheim
Jardiance
Flag link:

Pages